AstraZeneca Annual Report and Form 20-F Information 2011

Shareholder Information> For shares listed on the LSE the reported high and low middle market closing quotations are derived from the Daily Official List.> For shares listed on the SSE the high and low closing sales prices are as stated in the Official List.> For ADSs listed on the NYSE the reported high and low sales prices are as reported by Dow Jones (ADR quotations).Ordinary LSE ADS Ordinary SSEHigh (pence) Low (pence) High (US$) Low (US$) High (SEK) Low (SEK)2010 – Quarter 1 3102.5 2732.0 50.40 43.05 363.8 310.1– Quarter 2 3169.0 2772.0 48.74 40.91 368.0 314.0– Quarter 3 3385.0 3051.5 53.41 47.05 382.2 345.0– Quarter 4 3359.0 2922.0 53.50 45.80 354.7 309.32011 – Quarter 1 3073.5 2801.5 49.38 45.40 320.6 289.0– Quarter 2 3194.0 2895.0 52.40 46.60 328.5 294.2– Quarter 3 3166.5 2543.5 51.08 40.95 324.5 269.3– Quarter 4 3080.5 2731.5 49.89 42.53 319.0 293.7– July 3166.5 2973.0 51.08 48.51 324.5 309.0– August 2950.5 2543.5 48.26 40.95 304.1 269.3– September 2916.0 2738.5 46.69 42.64 305.1 284.0– October 3080.5 2814.5 49.89 43.86 319.0 299.5– November 2976.5 2731.5 47.88 42.53 316.2 293.7– December 2975.0 2883.0 46.34 45.15 318.2 307.0Major shareholdingsAt 2 February 2012, the following had disclosed an interest in the issued Ordinary Share capital of the Company in accordance with therequirements of rule 5.1.2 of the UK Listing Authority’s Disclosure and Transparency Rules:Date ofdisclosure toCompany 1Percentage ofissued sharecapitalNumber ofShareholdersharesBlackRock, Inc. 100,885,181 8 December 2009 7.87Invesco Limited 72,776,277 6 October 2009 5.67Axa SA 56,991,117 3 February 2009 4.44Investor AB 51,587,810 2 February 2012 4.02Legal & General Investment Management Limited 57,675,232 5 August 2010 4.501Since the date of disclosure to the Company, the interest of any person listed above in Ordinary Shares may have increased or decreased. No requirement to notify the Company of any increase ordecrease would have arisen unless the holding moved up or down through a whole number percentage level. The percentage level may increase (on the cancellation of shares following a repurchaseof shares under the Company’s share repurchase programme) or decrease (on the issue of new shares under any of the Company’s share plans).No other person held a notifiable interest in shares, comprising 3% or more of the issued Ordinary Share capital of the Company.Changes in the percentage ownership held by major shareholders during the past three years are set out below. Major shareholders do nothave different voting rights.Percentage of issued share capitalShareholder 2 Feb 2012 27 Jan 2011 28 Jan 2010 29 Jan 2009BlackRock, Inc. 7.87 7.18 6.94 –Invesco Limited 5.67 5.18 5.01 –Axa SA 4.44 4.06 3.92 4.90Investor AB 4.02 3.67 3.55 4.38Legal & General Investment Management Limited 4.50 4.10 4.64 4.09Capital Research and Management Company – – – 4.92Wellington Management Co., LLP – – – 4.18Barclays PLC – – – 4.26ADSs evidenced by ADRs issued by JPMorgan, as depositary, are listed on the NYSE. At 2 February 2012, the proportion of Ordinary Sharesrepresented by ADSs was 8.66% of the Ordinary Shares outstanding.Number of registered holders of Ordinary Shares at 2 February 2012:> In the US 766> Total 119,039Number of record holders of ADRs at 2 February 2012:> In the US 2,165> Total 2,176So far as the Company is aware, it is neither directly nor indirectly owned or controlled by one or more corporations or by any government.204 Shareholder InformationAstraZeneca Annual Report and Form 20-F Information 2011